What is Jade Biosciences, Inc. Common Stock's market cap?

Jade Biosciences, Inc. Common Stock (JBIO) has a market capitalization of $1.3B and trades on NASDAQ.

Who are Jade Biosciences, Inc. Common Stock's competitors?

Jade Biosciences, Inc. Common Stock's key competitors include Vera Therapeutics, Inc., Vertex Pharmaceuticals Incorporated, Travere Therapeutics, Inc., and others. These companies compete in similar markets and product categories.

Who does Jade Biosciences, Inc. Common Stock partner with?

Jade Biosciences, Inc. Common Stock's notable partners include Paragon Therapeutics, Inc., WuXi Biologics, Thermo Fisher Scientific, Inc., and others.

What subsidiaries does Jade Biosciences, Inc. Common Stock have?

Jade Biosciences, Inc. Common Stock's subsidiaries include Jade Biosciences, LLC.

Where is Jade Biosciences, Inc. Common Stock headquartered?

Jade Biosciences, Inc. Common Stock is headquartered in United States of America. It has been publicly traded since 2025.

Jade Biosciences, Inc. Common Stock

JBIO

Jade Biosciences is a clinical-stage biopharmaceutical company focused on developing novel biologic therapies for autoimmune diseases.

Market cap

$1.33B+318%

Net income-$129.6M-27.1%

Free cash flow-$94.9M-66.7%

EPS (diluted)-$2.02+93.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

EPS-$0.57Miss by $0.05

Read the full report

Next report

Aug 12, 2026 (in 2 months)

EPS estimate-$0.66

Financials

Q1 2026

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation & ratios

Valuation

See full

Market cap$1.33B+318%

Enterprise value$1.28B—

Returns & leverage

See full

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Competitors

By market cap

Vertex Pharmaceuticals$120.61B

Travere Therapeutics, Inc.$5.4B

Vera Therapeutics$2.8B

AnaptysBio, Inc.$1.7B

Jade Biosciences, Inc. Common Stock$1.3B

Avalo Therapeutics$954.6M

Vor Biopharma$784.6M

Climb Global Solutions, Inc.$411.7M

By revenue growth

AnaptysBio, Inc.+108%

Travere Therapeutics, Inc.+96.0%

Vertex Pharmaceuticals+10.1%

Avalo Therapeutics-38.0%

By net margin

Vertex Pharmaceuticals35.51%

Travere Therapeutics, Inc.-20.32%

AnaptysBio, Inc.-49.94%

Avalo Therapeutics-7,965.76%

Profile

Jade Biosciences is a clinical-stage biopharmaceutical company focused on developing novel biologic therapies for autoimmune diseases. The company leverages protein engineering to create monoclonal antibodies with improved potency and extended half-lives compared to existing treatments. Its core value proposition centers on delivering enhanced clinical activity and more convenient subcutaneous dosing regimens for patients with high unmet medical needs.

Competitive position

Clinical-stage developer focusing on best-in-class biologic profiles through half-life extension and increased binding affinity.

GeographiesUnited States, New Zealand

Customer segmentsPatients, Healthcare Providers

Business modelDrug Development, IP Licensing

SuppliersContract Research Organizations, Contract Manufacturing Organizations, Antibody Discovery Platforms

CustomersSpecialty Pharmacies, Hospitals, Infusion Centers

CountryUnited States of America

Listed2025

CEOTom Frohlich

SectorPHARMACEUTICAL PREPARATIONS

IndustryPHARMACEUTICAL PREPARATIONS

Websitejadebiosciences.com

FilingsSEC EDGAR

Questions, answered.

What is Jade Biosciences, Inc. Common Stock's market cap?: Jade Biosciences, Inc. Common Stock (JBIO) has a market capitalization of $1.3B and trades on NASDAQ.
Who are Jade Biosciences, Inc. Common Stock's competitors?: Jade Biosciences, Inc. Common Stock's key competitors include Vera Therapeutics, Inc., Vertex Pharmaceuticals Incorporated, Travere Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
Who does Jade Biosciences, Inc. Common Stock partner with?: Jade Biosciences, Inc. Common Stock's notable partners include Paragon Therapeutics, Inc., WuXi Biologics, Thermo Fisher Scientific, Inc., and others.
What subsidiaries does Jade Biosciences, Inc. Common Stock have?: Jade Biosciences, Inc. Common Stock's subsidiaries include Jade Biosciences, LLC.
Where is Jade Biosciences, Inc. Common Stock headquartered?: Jade Biosciences, Inc. Common Stock is headquartered in United States of America. It has been publicly traded since 2025.